These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18821717)

  • 1. Prescriber adoption of newly approved selective COX-2 inhibitors.
    Layton D; Souverein PC; Heerdink ER; Shakir SA; Egberts AG
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1168-74. PubMed ID: 18821717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal.
    Sukel MP; van der Linden MW; Chen C; Erkens JA; Herings RM
    Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):9-19. PubMed ID: 17963198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors.
    Schneeweiss S; Glynn RJ; Avorn J; Solomon DH
    J Clin Epidemiol; 2005 Jan; 58(1):98-102. PubMed ID: 15649677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of the selection of coxibs over nonselective NSAIDs in an older Medicaid cohort.
    Shireman TI; Rigler SK
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):210-8. PubMed ID: 17062321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.
    Layton D; Souverein PC; Heerdink ER; Shakir SA; Egberts AC
    Drug Saf; 2008; 31(2):143-58. PubMed ID: 18217790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study.
    Sebaldt RJ; Petrie A; Goldsmith CH; Marentette MA
    Am J Manag Care; 2004 Nov; 10(11 Pt 1):742-50. PubMed ID: 15623264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
    Rahme E; Toubouti Y; Hunsche E
    Rheumatology (Oxford); 2006 Jul; 45(7):903-10. PubMed ID: 16461440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coxibs: evolution of prescription's behaviour in France.
    Biga J; Gony M; Bourrel R; Souche A; Sommet A; Pathak A; Sciortino V; Taboulet F; Grand A; Lapeyre-Mestre M; Montastruc JL
    Fundam Clin Pharmacol; 2007 Jun; 21(3):317-25. PubMed ID: 17521301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motivations and perceived influences on rural and urban general practitioners when prescribing conventional non-steroidal anti-inflammatory drugs or COX-2 inhibitors.
    Behan K; Cutts C; Tett SE
    J Clin Pharm Ther; 2005 Aug; 30(4):337-43. PubMed ID: 15985047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoption of celecoxib and rofecoxib: a nationwide database study.
    Helin-Salmivaara A; Huupponen R; Virtanen A; Klaukka T
    J Clin Pharm Ther; 2005 Apr; 30(2):145-52. PubMed ID: 15811167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving medication safety: influence of a patient-specific prescriber feedback program on rate of medication reviews performed by Australian general medical practitioners.
    Roughead E; Pratt N; Peck R; Gilbert A
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):797-803. PubMed ID: 17476702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals.
    Greenberg JD; Bingham CO; Abramson SB; Reed G; Kishimoto M; Hinkle K; Kremer J
    Arthritis Rheum; 2006 Aug; 55(4):543-50. PubMed ID: 16874798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs.
    Patino FG; Allison J; Olivieri J; Mudano A; Juarez L; Person S; Mikuls TR; Moreland L; Kovac SH; Saag KG
    Arthritis Rheum; 2003 Jun; 49(3):293-9. PubMed ID: 12794782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs.
    Mosis G; Stijnen T; Castellsague J; Dieleman JP; van der Lei J; Stricker BH; Sturkenboom MC
    Arthritis Rheum; 2006 Aug; 55(4):537-42. PubMed ID: 16874797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.
    Depont F; Fourrier A; Merlière Y; Droz C; Amouretti M; Bégaud B; Bénichou J; Moride Y; Velo GP; Sturkenboom M; Blin P; Moore N;
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):891-900. PubMed ID: 17351983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals.
    Schüssel K; Schulz M
    Pharmazie; 2006 Oct; 61(10):878-86. PubMed ID: 17069430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analgesic prescribing for musculoskeletal complaints in the ambulatory care setting after the introduction and withdrawal of cyclooxygenase-2 inhibitors.
    Wilson RD
    Arch Phys Med Rehabil; 2009 Jul; 90(7):1147-51. PubMed ID: 19577028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comorbid conditions in the AMICA study patients: effects on the quality of life and drug prescriptions by general practitioners and specialists.
    Caporali R; Cimmino MA; Sarzi-Puttini P; Scarpa R; Parazzini F; Zaninelli A; Ciocci A; Montecucco C
    Semin Arthritis Rheum; 2005 Aug; 35(1 Suppl 1):31-7. PubMed ID: 16084231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.
    Barozzi N; Tett SE
    Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linking community pharmacy dispensing data to prescribing data of general practitioners.
    Florentinus SR; Souverein PC; Griens FA; Groenewegen PP; Leufkens HG; Heerdink ER
    BMC Med Inform Decis Mak; 2006 Apr; 6():18. PubMed ID: 16584557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.